Transcript Presentation
Environmental Sustainability at Novartis
Novartis North American HSE & BC 2013 ISPE- NJ Supplier Showcase, September 12
We work responsibly and ethically
Our patients and customers expect us to do business responsibly and ethically. We want to work with others to help address some of the world’s biggest health challenges.
We focus our
corporate responsibility
work in three areas:
1
Reaching more patients
Expanding access to healthcare
R&D for rare and neglected diseases Malaria Initiative Leprosy elimination Social business models: Arogya Parivar
2
Collaborating for results
Listening to and working with our stakeholders
Stakeholder engagement NGO relationships Novartis perspectives and positions
3
Doing business responsibly
Striving for operational excellence
Caring for our associates Protecting the environment Promoting ethics and strengthening governance 2 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Access-to-medicine programs – in 2011 we supported 89 million patients
Coartem ® delivered without profit
More than 80 million malaria patients treated
Leprosy medicine donated through WHO
Extended donation agreement to 2020
Tuberculosis medicine donations
More than 100,000 treatments delivered
Glivec ® /Tasigna ® patient assistance
Provided to 47,000 patients in about 80 countries
2011 Programs and research valued at USD 1.7 bn 3 Contributed 3% of net sales NITD 1 in Singapore
Focus on tuberculosis, dengue fever and malaria
NVGH 2 in Siena, Italy
Vaccines research institute for neglected diseases
1 Novartis Institute for Tropical Diseases; 2 Novartis Vaccines Institute for Global Health; 3 Based on approximate market value
3 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Novartis Code of Conduct and HSE mission
Novartis Health, Safety and Environment Mission
To be a leader in health, safety and environmental protection, as an integral part of the business, for the benefit of our associates and other stakeholders
Environment in the Code of Conduct
We make efficient use of natural resources and minimize the environmental impact of our activities and products over their life cycle.
4 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
The value added by HSE & BCM
5 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Commitment to the environment
“Protecting the environment is an integral part of business strategy in all divisions and business units. By balancing our economic, social and environmental objectives we aim to have a long term sustainable business.”
Keith Saveal Head Corporate HSE, Novartis 6 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Product value chain
Business process functions manage the value chain: Research Up-streams Development Down-streams Procurement Raw Materials Inter mediates Supply Manufacturing
TechOps
Infrastructure Delivery Distribution Marketing & Sales CommOps 7 | Environmental Sustainability at Novartis | August 2013 | Business Use Only Product Use End of Life
Mapping relevant environmental aspects
Raw Materials Inter mediates Supply NVS Operations Delivery Product Use End of Life
Sustainable Packaging
Materials Water Energy GHG Pr. Subs.
Air Emis.
Effluents Waste Contamin.
Energy & Climate Energy
Climate
PiE Legacy sites
PiE
8 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Why Environmental Footprint over the Live Cycle?
Growing interest in environmental impacts outside the company boundary Requests for information on supply chain from
stakeholders
and sustainability
rating agencies
Stakeholder
concerns
related to potential environmental impacts (micro pollutants) from pharmaceutical
product use and disposal
Trends with respect to increasing
outsourcing
patterns and change of production
Globalization
of business and of the value chain In 2009 we did a Scope 3 GHG emission estimation for Novartis overall with following results: • Raw material generation may represent the largest carbon impact • Other relevant impacts are waste disposal, infrastructure, business travel and packaging material disposal 9 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Objectives for our Life Cycle Assessment (LCA) work
Gain
better understanding
of impacts (carbon, waste, water, eco toxicity, etc.) and assessment methodologies Learn how to use
tools
effectively Develop an understanding of
relevant influencing factors
and product specific parameters that determine the impact Raise awareness for these factors and how they can be
influenced
in the business Find ways to
reduce
relevant life cycle impacts for the benefit of clients, the company and the environment 10 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Life Cycle Analysis Learning
What did we learn from Cradle-to-grave LCA / Supply Chain Carbon Footprint: • Pharma product impact overall is small: 10kg CO 2 e for annual patient dose = driving 35km • Impact from materials (solvents, intermediates) purchased from the supply chain is dominant (60%) • Potential end-of-live impact (Pharmaceuticals in the Environment) is not well reflected in a Carbon Footprint analysis • Internal transportation and distribution (for high volume products) are marginal What did we learn from Cradle-to-gate Carbon Footprinting for APIs: • Synthetic APIs have a clearly higher impact than Bio-tech APIs (170 versus 17tCO 2 e/t) • Energy is the dominant factor in Bio-tech (80%) • Supply chain and internal transportation are marginal (2%) 11 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Influencing factors
What type of API generation do we have (synthetic versus fermentation/bio-tech)?
What is the molecule (how complex is its chemical synthesis)?
What is the physiological activity of the molecule (what is the dose required)? What (supply and distribution) logistics have we chosen?
What is the environmental effect potential after use (PiE); what measures are necessary to keep the environmental impact marginal?
Which improvements count the most?
12 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Green Chemistry
Designing more sustainable medications
ACS GCI Roundtable Green chemistry in practice • Telescoping • Solvent elimination Supply Chain • Green Solvents • Critical mass "No endorsement or approval by the ACS GCI Pharmaceutical Roundtable has been received or is in any way implied." 13 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Environment and Energy
Strategic Objectives
Minimize risk related to Pharmaceuticals in the Environment (PiE) Pharmaceuticals in the Environment Sustainable packaging Leader in environmental sustainability Leading position on energy and climate Stringent management of environmental liabilities and legal compliance 14 | Environmental Sustainability at Novartis | August 2013 | Business Use Only GHG emission reductions and Carbon offsetting Contaminated sites
Pharmaceuticals in the Environment
Novartis Position Minimize environmental impact of activities and products over life cycle; work with suppliers No risk for human health; implications for aquatic wildlife limited or inconclusive • • • • Four-fold strategy, applies to all operations involved in R&D, production and disposal
Environmental risk assessment:
evaluate impact of new products before reaching the marketplace
Manufacturing:
minimize discharge of APIs from operations; take appropriate corrective measures
Save disposal:
do not dispose waste containing APIs into landfills; recommend avoiding disposal into sewers or landfills; welcome state-of-art waste water treatment and processes/system to ensure incineration
Increase knowledge:
support academia and regulators to close data gaps 15 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Three pathways into the environment
Patient use
•
Excretion, washing off the skin
•
Hospitals / retirement homes
•
Extent of metabolization
Upgrade of public waste water treatment
Incorrect disposal
•
Toilet flushing
•
Landfill of household waste
•
Take-back schemes (e.g. Spain)
Collection / take-back schemes, consumer education
Factory effluents
•
ChemOps, PharmOps sites
•
API suppliers and formulation contractors
Site special waste water treatment, operational measures 16 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Novartis Vision on Sustainable Packaging
“Consistent with our goal to be the most respected health care company, Novartis will design and utilize packaging solutions that minimize the impact on the environment while meeting all design, functional, regulatory and quality requirements that our patients and customers expect.” Developed by the Sustainable Packaging Committee, approved by HSE SteCom and endorsed by ECN in Nov 2010 17 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Savings achieved with packaging improvements
Savings from 20 projects between 2008 and 2012
Cost Materials GHG emissions Other USD
2.7mio
572
t of carton / plastic / metals more than
133
tCO 2 e
30
%
reduction weight Storage space Lead time Work load Waste 18 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Elimination of plastics in Lamisil Gel packaging
BEFORE
High-end package with a strong visual statement Very complex and labor intensive
AFTER
Several re-designs of package leading to USD 189,000 of cost saved Complete elimination of plastics Reduced packaging complexity Overall high-impact appearance of the product kept 19 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Design guide on Sustainable Packaging
Principles of Sustainable Packaging • Material selection 1. Choose materials with lower environmental impact 2. Reduce number of different materials • Design and size of the package 3. Reduce total amount of materials 4. Reduce excess volume 5. Reduce number of layers • Procurement of packaging materials 6. Purchase from environmentally and socially responsible suppliers 7. Consider certified/preferred materials 8. Consider local sources Specific questions on each level of packaging • Primary packaging • Secondary packaging • Tertiary packaging 20 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Energy and climate: commitment and targets
Climate commitment • • In 2001, Novartis joined the UN Global Compact In 2004, Voluntary “Kyoto” target set for global direct CO 2 emissions: Emit 5% less greenhouse gases (GHGs) by 2012 than in 1990; i.e. <293kt of Scope 1 on-site GHG emissions • In 2010, mid-term 15% reduction of total GHGs (Scope1 and Scope 2) by 2015, and long-term 20% reduction by 2020, based on 2008 levels To achieve these targets, Novartis employs a
dual strategy
• Improve
energy efficiency
and make use of
renewable resources
in order to keep energy use and GHG emissions at a minimum • Engage and participate in
“carbon offset“ projects
(sequestration) in order to compensate for part of the Novartis GHG emissions 21 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Successful energy savings by project
Novartis Group Energy Use and Energy Savings by Projects
Energy use and savings (in TJ) target 2015: 14.0% status 2012: 11.5% Energy costs and cost savings (in million USD)
2150TJ
USD 57mio
22 | Environmental Sustainability at Novartis| August 2013| Business Use Only
Energy Excellence Awards
Proven success with the Energy Excellence Awards (EEA) over last years • • • In eight years, the EEA scheme has: Generated over 500 projects totaling more than USD 100 million in cost savings Saved 4,000 terajoules 350 kiloton reduction of GHG, which equals the total emissions of the Novartis Group’s 30 000 vehicles over 2 years • Created tangible, replicable best practices The awards are perceived as a highly prestigious prize with senior management support Associates are motivated to “compete with the best” 23 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Planting trees to capture CO
2
and foster biodiversity
3 mio in Argentina 9 mio in China by 2014
Improve 12 mio boiler trees KPIs
4 Mt of carbon over 30 years Natural forests primarily based on native species Wood product business managed by principles of the Forest Stewardship Council Two UN registered projects (Argentina, China) one VCS (Mali) Social and environmental benefits 24 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
Contributing to rural development in Mali with plantation of Jatropha
5,000ha of Jatropha planted by more than 5,000 local farmers 200kt of carbon by 2020 Jatropha oil used for rural electrification, soap, bio-fertilizer by-product Supplemental income for farmers Protects food crops Protects fields from soil erosion and counters desertification 25 | Environmental Sustainability at Novartis | August 2013 | Business Use Only
2012 Kyoto target achieved
Novartis on-site Scope1 GHG emissions by 2012 (excl. Alcon) are 5% below 1990, i.e.: 293kt Results: •
Emissions:
2012 emission were 409kt. The needs from offset projects is therefore at least 116kt.
•
Offsets:
Argentina reached 118kt by year end 2012. The Mali project gave only about 1.1kt offsets.
•
Result:
Emissions Offsets Balance = 409kt = 119kt = 290kt
Kyoto target achieved!
26 | Environmental Sustainability at Novartis | August 2013| Business Use Only kt
Offsets Kyoto target Scope1 GHG